Oncobiologics (NJ-based, private) inks FoB partnership with Zhejiang Huahai Pharmaceutical Co. for unspecified FoB’s for China and other markets (including the US); for countries outside of China, the partners will seek a third company for marketing:
‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually.
@ Samsung/BIIB subordinate collaboration known as Samsung Bioepis; Rituxan program terminated (#msg-80622249); presumably excludes FoB’s for BIIB’s branded drugs.
#Humira, Rituxan, Avastin, Herceptin.
x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.
y Rituxan program terminated (#msg-80236315); status of other programs unknown.